Neri Jesse 4/A

What Happened

• Jesse Neri, Senior Vice President and Chief Financial Officer of Rockwell Medical, received a grant of 97,500 performance-based restricted stock units (PSUs) on 2025-05-20. The award is reported as a derivative grant with an acquisition price of $0.00 (no cash paid). This amended Form 4 states the award was inadvertently omitted from the original filing.

Key Details

• Transaction date: 2025-05-20 (reported via amended Form 4 filed 2026-04-17).
• Instrument/type: 97,500 PSUs (derivative award) at $0.00 per unit (grant).
• Shares owned after transaction: not specified in this filing.
• Footnote (material): PSUs vest only if a performance hurdle is met during the three‑year performance period; vesting can occur on or after the first anniversary of the grant date. The hurdle requires the average closing price over any 60 consecutive trading days to equal two times the base price. Base price for this award = $2.14, so the 60-day average target = $4.28. Any unvested PSUs remaining after the three‑year term are cancelled.
• Filing status: This is an amended filing (the award was omitted from the original Form 4), so the report is late relative to the grant date.

Context

• PSUs are contingent awards that convert to shares only if specified performance and time-based conditions are met; they are not immediate stock purchases. Because vesting depends on a future stock-price performance hurdle, these awards do not necessarily reflect an immediate change in insider share ownership or cash flow.